Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Athersys, Inc. (ATHX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.8200+0.0700 (+4.00%)
At close: 04:00PM EST
1.7200 -0.10 (-5.49%)
After hours: 07:15PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close1.7500
Open1.7800
Bid1.7600 x 1100
Ask1.8800 x 2900
Day's Range1.7100 - 1.9100
52 Week Range0.5000 - 33.2500
Volume601,695
Avg. Volume689,616
Market Cap31.32M
Beta (5Y Monthly)-0.67
PE Ratio (TTM)1.18
EPS (TTM)1.5400
Earnings DateMar 13, 2023 - Mar 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ATHX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Athersys, Inc.
    Analyst Report: Incyte CorporationIncyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • Business Wire

    Athersys to Host Business Update Conference Call on February 14th

    CLEVELAND, February 02, 2023--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert "Willie" Mays, Executive Vice President Regenerative Medicine and Head of N

  • Business Wire

    Athersys to Participate in International Stroke Conference and BioProcess International

    CLEVELAND, January 30, 2023--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in two upcoming conferences, the International Stroke Conference 2023 (ISC) from February 8-10, 2023 in Houston, TX and BioProcess International US West from February 27-March 2, 2023 in San Diego, CA. Any registered attendees interested in meeting with Athersys at either conference can

  • American City Business Journals

    Athersys shares take a wild ride while executives meet with investors

    If the company's stock price stays above $1 for 10 consecutive business days, Athersys will regain compliance with a Nasdaq listing requirement.

Advertisement
Advertisement